Frontlight ResearchEarly access
CompletedPhase 1/2
An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)
Key facts
- Who runs it
- JCR Pharmaceuticals Co., Ltd.
- Where
- Oakland, United StatesSee the siteAlso in 2 other countries, 5 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 14 people enrolled
- Started
- 28 Oct 2021
- Ended
- 2 May 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- JR-171
- Record updated
- 28 August 2025
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients who have completed the Part 2 of JR-171-101 study
- A patient from whom written informed consent can be obtained. If the patient is aged under 18 years (20 years in case of Japan) at the time of assent or willingness to participate in the study cannot be confirmed due to MPS I-related intellectual disability, informed permission from the patient's legally acceptable representative (e.g., his/her parents or guardians) need to be obtained instead of his/her consent. Even in this case, written informed consent should be obtained from the patient, wherever possible
- Female patient or male patient whose co-partners is of child-bearing potential agree to use a medically accepted, highly effective method of contraception, such as spermatocidal gel plus condom, an intrauterine device or oral contraceptives until one month after the final administration
Who cannot take part
- Judged by the principal investigator or subinvestigator to be ineligible to participate in the study due to a history of a serious drug allergy or hypersensitivity to any drugs
- A patient who is unable to perform the study procedures, except for 6-minute walk test, neurocognitive testing, BVMT-R, HVLT-R, and T.O.V.A
- Judged by the principal investigator or subinvestigator as being unable to undergo lumbar puncture, including those who have difficulties in taking a position for lumbar puncture due to joint contracture or those who are likely to experience difficulty breathing during the lumbar puncture process
- Otherwise judged by the principal investigator or subinvestigator to be ineligible to participate in the study in consideration of patient's safety
Where in United States
Also in 2 other countries, 5 sites
- UCSF Benioff Children's Hospital OaklandOakland, United States
About the trial
What the trial wants to find out
Phase I/II, open label, multicenter, multinational (Japan, Brazil and the US) extension study of JR-171-101 (NCT04227600) for the treatment of MPS I
The 2 groups in the trial
- Dose level 1Treatment being tested
2.0 mg/kg/week
Treatment: JR-171
- Dose level 2Treatment being tested
4.0 mg/kg/week
Treatment: JR-171
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I
- Record updated
- 28 August 2025